Fabián Vázquez-Santiago1, Yashira García1, Ivelisse Rivera-Román1, Richard J Noel2, Valerie Wojna3, Loyda M Meléndez4, Vanessa Rivera-Amill1. 1. Department of Microbiology, Ponce Health Sciences University- School of Medicine/Ponce Research Institute, Ponce, PR 00716, USA. 2. Department of Biochemistry, Ponce Health Sciences University- School of Medicine/Ponce Research Institute, Ponce, PR 00716, USA. 3. Specialized NeuroAIDS Program, University of Puerto Rico-Medical Sciences Campus, San Juan, PR, 00936, USA ; Department of Internal Medicine, Neurology Division, University of Puerto Rico-Medical Sciences Campus, San Juan, PR 00936, USA. 4. Specialized NeuroAIDS Program, University of Puerto Rico-Medical Sciences Campus, San Juan, PR, 00936, USA ; Department of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR, 00936, USA.
Abstract
OBJECTIVE: Combined antiretroviral treatment (cART) has changed the clinical presentation of HIV-associated neurocognitive disorders (HAND) to that of the milder forms of the disease. Asymptomatic neurocognitive impairment (ANI) is now more prevalent and is associated with increased morbidity and mortality risk in HIV-1-infected people. HIV-1 envelope (env) genetic heterogeneity has been detected within the central nervous system (CNS) of individuals with ANI. Changes within env determine co-receptor use, cellular tropism, and neuropathogenesis. We hypothesize that compartmental changes are associated with HIV-1 env C2V4 during ANI and sought to analyze paired HIV-1 env sequences from plasma and cerebrospinal fluid (CSF) of a female subject undergoing long-term cART. METHODS: Paired plasma and CSF samples were collected at 12-month intervals and HIV-1 env C2V4 was cloned and sequenced. RESULTS: Phylogenetic analysis of paired samples consistently showed genetic variants unique to the CSF. Phenotypic prediction showed CCR5 (R5) variants for all CSF-derived sequences and showed minor X4 variants (or dual-tropic) in the plasma at later time points. Viral compartmentalization was evident throughout the study, suggesting that the occurrence of distinctive env strains may contribute to the neuropathogenesis of HAND. CONCLUSIONS: Our study provides new insights about the genetic characteristics within the C2V4 of HIV-1 env that persist after long-term cART and during the course of persistent ANI.
OBJECTIVE: Combined antiretroviral treatment (cART) has changed the clinical presentation of HIV-associated neurocognitive disorders (HAND) to that of the milder forms of the disease. Asymptomatic neurocognitive impairment (ANI) is now more prevalent and is associated with increased morbidity and mortality risk in HIV-1-infected people. HIV-1envelope (env) genetic heterogeneity has been detected within the central nervous system (CNS) of individuals with ANI. Changes within env determine co-receptor use, cellular tropism, and neuropathogenesis. We hypothesize that compartmental changes are associated with HIV-1env C2V4 during ANI and sought to analyze paired HIV-1env sequences from plasma and cerebrospinal fluid (CSF) of a female subject undergoing long-term cART. METHODS: Paired plasma and CSF samples were collected at 12-month intervals and HIV-1env C2V4 was cloned and sequenced. RESULTS: Phylogenetic analysis of paired samples consistently showed genetic variants unique to the CSF. Phenotypic prediction showed CCR5 (R5) variants for all CSF-derived sequences and showed minor X4 variants (or dual-tropic) in the plasma at later time points. Viral compartmentalization was evident throughout the study, suggesting that the occurrence of distinctive env strains may contribute to the neuropathogenesis of HAND. CONCLUSIONS: Our study provides new insights about the genetic characteristics within the C2V4 of HIV-1env that persist after long-term cART and during the course of persistent ANI.
Authors: Q Hu; J O Trent; G D Tomaras; Z Wang; J L Murray; S M Conolly; J M Navenot; A P Barry; M L Greenberg; S C Peiper Journal: J Mol Biol Date: 2000-09-15 Impact factor: 5.469
Authors: P R Gorry; G Bristol; J A Zack; K Ritola; R Swanstrom; C J Birch; J E Bell; N Bannert; K Crawford; H Wang; D Schols; E De Clercq; K Kunstman; S M Wolinsky; D Gabuzda Journal: J Virol Date: 2001-11 Impact factor: 5.103
Authors: Paul R Gorry; Joann Taylor; Geoffrey H Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven M Wolinsky; Dana Gabuzda Journal: J Virol Date: 2002-06 Impact factor: 5.103
Authors: Guido Van Marle; Sean B Rourke; Kunyan Zhang; Claudia Silva; Julie Ethier; M John Gill; Christopher Power Journal: AIDS Date: 2002-09-27 Impact factor: 4.177
Authors: Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins Journal: J Virol Date: 2003-12 Impact factor: 5.103
Authors: Corey A Williams-Wietzikoski; Isaac D So; Marta E Bull; Tanawan Samleerat; Kessara Pathanapitoon; Paradee Kunavisarut; Natedao Kongyai; Nicole Ngo-Giang-Huong; Lisa M Frenkel; Wasna Sirirungsi Journal: AIDS Date: 2017-08-24 Impact factor: 4.177
Authors: Kenta Matsuda; Nadeene E Riddick; Cheri A Lee; Sarah B Puryear; Fan Wu; Bernard A P Lafont; Sonya Whitted; Vanessa M Hirsch Journal: PLoS Pathog Date: 2017-08-07 Impact factor: 6.823
Authors: Nametso Kelentse; Sikhulile Moyo; Mompati L Mogwele; Doreen Ditshwanelo; Baitshepi Mokaleng; Natasha O Moraka; Kwana Lechiile; Tshepo B Leeme; David S Lawrence; Rosemary Musonda; Ishmael Kasvosve; Thomas S Harrison; Joseph N Jarvis; Simani Gaseitsiwe Journal: Viruses Date: 2020-12-07 Impact factor: 5.048